{"data":{"issuanceinfo":{"industrycode":"204005","industry":"醫療保健","ipoprice":{"ceiling":"33.000","floor":"29.000"},"ipodate":{"start":"2019-11-28 00:00:00","end":"2019-12-03 00:00:00"},"minimumcapital":"16666.28","subscribed":"312.42","marketcap":"129.59億","H_marketcap":"56.41億","pe":"--","codesrate":"30.00","link":"https://staticpdf.iqdii.com/stockdata/notice/02500/2019/2019112800030_c.pdf","ipopricing":"33.000","resultdate":"2019-12-09 00:00:00","enddate":"2019-12-03 00:00:00","listeddate":"2019-12-10 00:00:00","issuenumber":"7853.75萬","issuenumberhK":"3926.90萬","issuenumberother":"3926.85萬","grayprice":"39.40","sponsors":"高盛(亞洲)有限責任公司,中國國際金融香港證券有限公司,瑞士信貸(香港)有限公司,招商證券(香港)有限公司","raisemoney":"241100.00萬","use":"1、35.0%或約843.9百萬港元分配至我們的核心產品；\n2、30.0%或約723.3百萬港元分配至我們的其他產品及在研產品；\n3、10.0%所得款項凈額或約241.1百萬港元，為有關收購Keystone的代價付款及其他交易開支提供資金；\n4、15.0%所得款項凈額或約361.7百萬港元，為我們透過內部研究及/或潛在收購持續擴充產品組合提供資金；\n5、10.0%所得款項凈額或約241.1百萬港元，作營運資金及其他一般企業用途。","shares":500,"leadagent":"高盛(亞洲)有限責任公司,中國國際金融香港證券有限公司,瑞士信貸(香港)有限公司,招商證券(香港)有限公司,招銀國際融資有限公司,海通國際證券有限公司,中銀國際亞洲有限公司,農銀國際證券有限公司,香港上海匯豐銀行有限公司","bookrunners":"高盛(亞洲)有限責任公司,中國國際金融香港證券有限公司,瑞士信貸(香港)有限公司,招商證券(香港)有限公司,招銀國際融資有限公司,海通國際證券有限公司,中銀國際亞洲有限公司,農銀國際融資有限公司,香港上海匯豐銀行有限公司","coordinator":"高盛(亞洲)有限責任公司,中國國際金融香港證券有限公司,瑞士信貸(香港)有限公司,招商證券(香港)有限公司,招銀國際融資有限公司,海通國際證券有限公司","firstDayOpen":"40.00","IsEiio":0,"Interestdays":6,"PENote":"按經審核的最近年度公司股東應占溢利和發行后總股本計算；發行價未確定時，按招股價中間價計算；發行價確定后，按招股定價計算。","OverAllotment":"有","StabilizingManager":"高盛(亞洲)有限責任公司","code":"E02500","name":"啟明醫療－Ｂ","fullname":"杭州啟明醫療器械股份有限公司"},"institutioninfo":{"principaloffice":"中國杭州濱江區江陵路88號2幢3樓311室","registrars":"香港中央證券登記有限公司","registrarstel":"(852) 2862 8628","chairman":"曾敏","secretary":"馬海越,黃偉超","telephone":"(86571) 8675 9022","substantialshareholders":"Horizon Binjiang LLC(12.21%),Ming Zhi Investment (BVI) Limited(12%),訾振軍(7.87%),Broad Street Investments Holding (Singapore) Pte. Ltd.(7.17%),QM22 (BVI) Limited(5.19%)","principalactivities":"公司是中國領先的經導管心臟瓣膜醫療器械企業。","website":"http://www.venusmedtech.com/"},"managerinfo":[{"managername":"曾敏","post":"董事會主席兼執行董事","rankno":1},{"managername":"訾振軍","post":"執行董事兼總經理","rankno":2},{"managername":"林浩升","post":"執行董事","rankno":3}],"investorinfo":[{"institutionname":"Hillhouse Funds","shareholding":"11,857,500.0","percentage":15.1,"ReleaseDate":"2020-06-10 00:00:00","relatedparty":"Hillhouse Capital","subsidiary":["Gaoling Fund, L.P.","Hillhouse Funds","Gaoling Yali Fund, L.P.","HHJH Holdings Limited"],"InverstorType":"基金"},{"institutionname":"GIC Private Limited","shareholding":"7,114,500.0","percentage":9.06,"ReleaseDate":"2020-06-10 00:00:00","relatedparty":"","subsidiary":[],"InverstorType":"公司"},{"institutionname":"Aspex Master Fund","shareholding":"4,743,000.0","percentage":6.04,"ReleaseDate":"2020-06-10 00:00:00","relatedparty":"Aspex Management (Cayman) Limited","subsidiary":["Aspex Master Fund"],"InverstorType":"基金"},{"institutionname":"Cephei QFII China Total Return Fund Ltd.","shareholding":"4,743,000.0","percentage":6.04,"ReleaseDate":"2020-06-10 00:00:00","relatedparty":"鼎暉投資咨詢新加坡有限公司","subsidiary":["Cephei QFII China Total Return Fund Ltd."],"InverstorType":"基金"}],"TotalShareholdingPercentage":39.26},"result":1,"Version":"4.5.190802.46408","ElapsedMilliseconds":8}